Article

Compliance with recommended dosing intervals for HPV vaccination among females, 13-17 years, National Immunization Survey-Teen, 2008-2009

Immunization Services Division, Centers for Disease Control and Prevention, 1600 Clifton Road, MS A-19, Atlanta, GA 30333, United States.
Vaccine (Impact Factor: 3.49). 11/2011; 30(3):503-5. DOI: 10.1016/j.vaccine.2011.11.042
Source: PubMed

ABSTRACT Data from the 2008 and 2009 National Immunization Survey-Teen were analyzed to determine age at initiation of the human papillomavirus vaccine (HPV) series among females 13-17 years (n=7594) and assess compliance with the recommended HPV dosing intervals. Among females who initiated the HPV series, 56.7% of females<13 years at the time of the HPV vaccine recommendation publication did so by age 13; while the majority of females 13-14 and 15-17 years at the time of the recommendation publication did so at ages 14 (44.4%) and 16 (46.7%), respectively. Forty-six percent of females who received three doses completed the vaccination series in a period longer than the recommended time interval. Series completion at an earlier age to ensure protection before sexual debut is optimal. Improved provider communication of the need for three doses for long-term protection and implementing clinical practice guidelines to use reminder-recall systems may increase HPV completion.

0 Followers
 · 
78 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: To provide a clinically relevant synopsis of recent research findings as well as updated guidelines from the American Academy of Pediatrics and Advisory Committee on Immunization Practices regarding child and adolescent immunizations. Childhood vaccinations have served to dramatically reduce pediatric morbidity and mortality in the USA. Much of the recent research has focused on the improvement of current vaccines as well as on the development of new vaccines. By improving the safety, efficacy and immunogenicity of vaccinations, children can be more fully protected. Additionally, recommendations have broadened as vaccinations have been proven well tolerated and effective for a growing number of subpopulations. Although more groups of children are now included in vaccination recommendations, efforts must continue to ensure that all eligible children receive their vaccinations. This article reviews selected recent publications on influenza, human papillomavirus, the childhood and adolescent/adult formulations of diphtheria and tetanus toxoids and acellular pertussis, meningococcal conjugate and pneumococcal vaccines. The relationship between febrile seizures and childhood immunizations is explored. The research on childhood and adolescent vaccinations is continuously growing and will serve to shape future recommendations. Through their findings, we can learn how to optimize the protection of all children and adolescents against these very serious diseases.
    Current opinion in pediatrics 06/2012; 24(3):407-21. DOI:10.1097/MOP.0b013e3283534d11 · 2.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review To provide a clinically relevant synopsis of recent research findings as well as updated recommendations from the American Academy of Pediatrics (AAP) and Advisory Committee on Immunization Practices (ACIP) regarding adolescent immunizations. Recent findings Coverage rates for the adolescent vaccinations continue to lag behind those of the childhood vaccinations, despite their importance. Recent research has focused on the reasons for suboptimal adolescent vaccination rates as well as strategies for improvement. By more fully understanding the barriers to immunization, efforts can be implemented to address these concerns and to ensure that all eligible adolescents receive their vaccinations. In addition, much work has focused on the duration of protection induced by childhood and adolescent vaccinations and the need for booster doses in older adolescents. Because immunity has been found to wane after vaccination, these booster doses can serve to more fully protect adolescents. This article reviews selected recent publications on human papillomavirus, meningococcal conjugate, and tetanus and diphtheria toxoids and acellular pertussis vaccines. Summary Adolescent vaccinations will continue to be studied and this research will serve to shape future recommendations. Through this work, we can learn the best methods to optimize the protection of all adolescents against these very serious diseases.
    Current Opinion in Pediatrics 01/2013; 25(3):397-406. DOI:10.1097/MOP.0b013e328360dc63 · 2.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Organized population-based HPV vaccination programs can be effective in reducing the burden of cervical cancer, especially in the absence of a comprehensive cervical screening program (e.g. Hong Kong). Assessment of vaccine acceptability is important when evaluating the feasibility and cost-effectiveness of such vaccination programs. To provide a more representative and updated assessment on the acceptability of female adolescent HPV vaccination in Hong Kong, we conducted surveys in 2008 among 1022 mothers with daughters aged ≤18 years through random digit-dialing telephone interviewing and 2167 schoolgirls aged 11-18 years using two-stage stratified cluster sampling. We conducted the maternal survey again in 2012 with an independent group of 1005 mothers. In 2008, 2.4% (95% confidence interval [CI]=1.8-3.2%) of the recruited schoolgirls reported having received HPV vaccination. In 2012, the mothers reported that 9.1% (7.0-11.6%) of their daughters who were in the same age range (11-18 years) as the schoolgirls had been vaccinated (p<0.01). Regarding acceptability, 27.5% (24.8-30.4%) and 37.6% (34.5-40.8%) of the mothers were willing to have their daughters vaccinated at market price in 2008 and 2012 (p<0.01), respectively. 27.1% (25.2-29.1%) of the schoolgirls were willing to receive HPV vaccination at market price in 2008. The willingness to pay for full-course vaccination among mothers had a median of US$128/HK$1000 (50% central range=US$64-192/HK$500-1500), i.e. substantially lower than the current market price. The gap between acceptability and actual uptake of HPV vaccination among adolescent girls suggested that coverage is likely to be low without an organized HPV vaccination program, although the difference might be partially attributed to the possibility that at the time of the interview female adolescents who were willing to be vaccinated had not yet taken action. Policymakers should devise tailored, targeted and efficient vaccination strategies to achieve universal coverage for an effectively organized HPV vaccination program.
    Vaccine 11/2013; 32(1). DOI:10.1016/j.vaccine.2013.10.068 · 3.49 Impact Factor
Show more